Valderrama, Begoña P.

Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma

Bajorin, D. F., Witjes, J. A., Gschwend, J. E., Schenker, M., Valderrama, B. P., Tomita, Y., Bamias, A., Lebret, T., Shariat, S. F., Park, S. H., et al. (2021) · New England Journal of Medicine

Bladder and Urothelial Cancer TreatmentsCancer Immunotherapy and Biomarkers

Cited by 1,065

Tailored immunotherapy approach with nivolumab with or without nivolumab plus ipilimumab as immunotherapeutic boost in patients with metastatic renal cell carcinoma (TITAN-RCC): a multicentre, single-arm, phase 2 trial

Grimm, M.-O., Esteban, E., Barthélémy, P., Schmidinger, M., Busch, J., Valderrama, B. P., Charnley, N., Schmitz, M., Schumacher, U., Leucht, K., et al. (2023) · The Lancet Oncology

Renal cell carcinoma treatmentCancer Immunotherapy and Biomarkers

Cited by 37

Subcutaneous versus intravenous nivolumab for renal cell carcinoma

Albiges, L., Bourlon, M. T., Chacón, M., Cutuli, H. J., Chuken, Y. A. L., Żurawski, B., Mota, J. M., Magri, I., Burotto, M., Luz, M., et al. (2025) · Annals of Oncology

Renal cell carcinoma treatmentCancer Immunotherapy and Biomarkers

Cited by 31

Clinical activity of durvalumab and savolitinib in MET-driven, metastatic papillary renal cancer.

Suarez Rodriguez, C., Larkin, J., Patel, P. M., Valderrama, B. P., Rodriguez-Vida, A., Glen, H., Thistlethwaite, F., Ralph, C., Srinivasan, G., Mendez-Vidal, M. J., et al. (2021) · Journal of Clinical Oncology

Renal cell carcinoma treatmentCancer Immunotherapy and Biomarkers

Cited by 14

Belzutifan (bel) plus lenvatinib (lenva) versus cabozantinib (cabo) for advanced renal cell carcinoma (RCC) after anti–PD-(L)1 therapy: Open-label phase 3 LITESPARK-011 study.

Motzer, R. J., Park, S. H., McDermott, R. S., Porta, C., Heng, D. Y. C., Burotto, M., Iacovelli, R., Verzoni, E., Cutuli, H., Haanen, J., et al. (2026) · Journal of Clinical Oncology

Renal cell carcinoma treatmentCancer Immunotherapy and Biomarkers

Cited by 9